Navigation Links
Lilly Reports First-Quarter 2011 Results
Date:4/18/2011

ighted-average sharesoutstanding (thousands) – diluted1,112,0261,103,406Eli Lilly and CompanyOperating Results  (Unaudited) – Non-GAAP (Dollars in millions, except per share data)Three Months EndedMarch 312011(a)  

2010(b)

% Chg.Total revenue

$

5,839.2

$

5,485.5

6%Cost of sales1,180.11,122.5

5%Research and development1,124.01,039.1

8%Marketing, selling and administrative1,785.71,614.4

11%Operating income 1,749.41,709.5

2%Net interest income (expense)(30.3)(37.0)Net other income (expense)19.1111.5Other income  (expense)(11.2)74.5

NMIncome before income taxes1,738.21,784.0

(3)%Income taxes363.3486.4

(25)%Net income

$

1,374.9

$

1,297.6

6%Earnings per share – basic

$

1.24

$

1.18

5%Earnings per share – diluted

$

1.24

$

1.18

5%Dividends paid per share

$

0.49

$

0.49

NMWeighted-average sharesoutstanding (thousands) – basic1,112,0031,103,380Weighted-average sharesoutstanding (thousands) – diluted1,112,0261,103,406

  1. The first quarter 2011 has been adjusted to eliminate a restructuring charge of $76.3 million (pretax), or $0.06 (after-tax). This charge is related to severance costs from previously announced strategic actions that the company is taking to reduce its cost structure and global workforce. In addition, the first quarter 2011 financial statements have been adjusted to eliminate a charge of $388.0 million (pretax), or $0.23 per share (after-tax), for acquired in-process research and development associated with the collaboration with Boehringer Ingelheim.
  2. The first quarter 2010 has been adjusted to eliminate a restructuring charge of $26.2 million (pretax), or $0.02 (after-tax). This charge is primarily related to severance costs from prev
    '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Intelomed is pleased to announce that ... as the Vice President of Clinical Affairs. With over ... device industry, Kay,s experience in taking medical technology and ... to global expansion, is a valuable addition to the ... on our team, and I am confident her focused ...
(Date:8/26/2014)... , Aug. 26, 2014 Blue Bell, Pennsylvania ... office worldwide. PRA, a leading global Contract Research Organization (CRO), is ... Fort Washington locations into new modern Class A+ ... office opened this week and marks the first phase of the ... us at PRA," said Harris Koffer , President of the ...
(Date:8/26/2014)... comes to diabetes supplies, innovations are often accused of ... answer a real medical need. Fitting ... shows how long it,s been since your last injection. ... insulin doses. Very easy to use, Timesulin starts automatically ... after an injection. There is no settings or complicated ...
Breaking Medicine Technology:Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2PRA Health Sciences Expands in Pennsylvania 2Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
... TEL AVIV, Israel, August 18 ... frequency solution for,facial and body contouring, has been ... or striae distensae. The peer reviewed paper entitled,"Treatment ... a,pilot study" authored by Dr Manuskiatti et al, ...
... Stereotactic body radiotherapy (SBRT) is a highly effective alternative treatment ... from The University of Texas in Houston, according to James G. ... Palm Beach. , ( www.cyberkni f em ... data confirms the established method of cancer treatment used on spinal ...
Cached Medicine Technology:Clinical Study Proves Pollogen's TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks 2New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors 2
(Date:8/27/2014)... Chicago, Illinois (PRWEB) August 27, 2014 ... integration project in the US with Buzz™ Digital O.R. ... The foundation of all 13 new operating rooms will ... control and management. This integrative system supports planning, navigation, ... is an advanced fusion of intuitive software and hardware ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
(Date:8/27/2014)... microGUNE, the Co-operative Research Centre into Microtechnologies, ... to generate innovative solutions based on microtechnologies ... industry and life sciences, among others. IK4-Ikerlan, ... are collaborating with CIC microGUNE on this ... by the Etortek 2013-2014 programme of the ...
(Date:8/27/2014)... water and oil and are persistent towards aggressive ... characteristics have made the fluorochemicals useful in numerous ... paper and board. , The problem with fluorochemicals ... and accumulate in both humans and the environment. ... effects, such as cancer, increased cholesterol and a ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3
... many aren,t getting preventive treatments , , THURSDAY, Jan. ... patients in hospitals worldwide risk developing dangerous blood ... receiving treatments that could prevent the condition, a ... long been recognized to be one of the ...
... NEW YORK, Jan. 31 QED International Associates, ... 20 underlying,indexes for the HealthShares(TM) Exchange-Traded Funds, today ... Monday February 4, 2008,BioMerieux Worldwide (Euronext: BIM) will ... European Medical Products and Devices Index., Companies ...
... But analysis calls gap between these and lower-tier facilities ... admitted to the top-rated hospitals in the United States ... than patients admitted to other hospitals in the country, ... an independent health-care ratings organization, the analysis of 27 ...
... Set for February 29, 2008, PALO ALTO, ... JAZZ ) announced today that the U.S. Food ... submission of the,response by Solvay Pharmaceuticals, Inc. to ... maleate) Extended-Release Capsules. The,FDA has notified Solvay Pharmaceuticals ...
... N.J., Jan. 31 Medarex, Inc.,(Nasdaq: MEDX ) ... the,Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device,Conference at ... event will be,webcast live and will be available in ... http://www.medarex.com . An archived edition of the,presentation will ...
... Jan. 31 Acura,Pharmaceuticals, Inc. (OTC Bulletin Board: ... Market(R) has approved the Company,s application to,list its ... The,Company,s common stock will commence trading on NASDAQ ... "We are pleased to join the growing ...
Cached Medicine News:Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
... Small Volume Medication Mouthpiece 7FT O 2 ... advanced jet design for fast treatment times , ... a tighter distribution (higher percentage of respirable particles) ... AirLife™ brand Misty Max 10™ disposable nebulizers deliver ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: